Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: A comparative study of the efficacy and safety against amlodipine

Clinical Pharmacology and Therapeutics

Volumn 60, Issue 3, 1996, Pages 341-346

  Corea, Luigi ^a   Cardoni, Ondina ^a   Fogari, Roberto ^a   Innocenti, Pierfranco ^a   Porcellati, Carlo ^a   Provvidenza, Michele ^a   Meilenbrock, Susanne ^a   Sullivan, John ^a   Bodin, Frédéric ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANGIOTENSIN II ANTAGONIST; VALSARTAN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; ESSENTIAL HYPERTENSION; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; TACHYCARDIA; VERTIGO;

ADULT; AGED; AMLODIPINE; ANGIOTENSIN II; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; DIZZINESS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; EDEMA; FEMALE; HEADACHE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; RECEPTORS, ANGIOTENSIN; TETRAZOLES; TREATMENT OUTCOME; VALINE;

EID: 0029807227     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(96)90061-2     Document Type: Article

References (13)

1. Sever P, Beevers G, Bulpitt C, Lever A, Ramsay L, Reid J, et al. Management guidelines in essential hypertension: report of the second working party of the British Hypertension Society. BMJ 1993;306:983-7.
2. Subcommittee of WHO/ISH Mild Hypertension Liaison Committee. Summary of 1993 World Health Organisation-International Society of Hypertension guidelines for the management of mild hypertension. BMJ 1993;307:1541-6.
3. The Fifth Report of the Joint National Committee of Detection, Evaluation, and Treatment of High Blood Pressure (JNCV). Arch Intern Med 1993; 153:154-83.
4. Weber MA. Clinical experience with the angiotensin II receptor antagonist losartan: a preliminary report. Am J Hypertens 1992;5:247S-51S.
5. Müller P, Cohen T, de Gasparo M, Sioufi A, Racine-Poon A, Howald H. Angiotensin II receptor blockade with single doses of valsartan in healthy, normotensive subjects. Eur J Clin Pharmacol 1994;47: 231-45.
6. Criscone L, Bradley WA, Buehlmayer P, White-bread S, Glazer R, Lloyd P, et al. Valsartan: preclinical and clinical profile of an antihypertensive angiotensin II antagonist. Cardiovasc Drug Rev 1995;13;230-50.
7. Webster J, Robb O, Jeffers TA, Scott AK, Petrie JC. Once-daily amlodipine in the treatment of mild to moderate hypertension. J Cardiovasc Pharmacol 1988;12:S72-5.
8. Kaplan NM. Amlodipine in the treatment of hypertension. Postgrad Med J 1991;67:S15-9.
9. Murdoch D, Heel RC. Amlodipine. Drugs 1991;41: 478-505.
10. 1989 Guidelines for the management of mild hypertension: memorandum from WHO/ISH meeting. J Hypertens 1989;7:689-93.
11. McHugh RB, Le CT. Confidence estimation and size of a clinical trial. Controlled Clin Trials 1984;5:157-63.
12. Tikkanen I, Omvik P, Jensen H. Comparison of the angiotensin II antagonist losartan with the angiotensin converting enzyme inhibitor enalapril in patients with essential hypertension. J Hypertens 1995;13: 1343-51.
13. Johnston CI. Angiotensin antagonists: focus on losartan. Lancet 1995;346:1403-7.